Remo CRO


Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes

07.03 2018.

SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 28, 2018– Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study… Details

Enteris BioPharma Announces Positive Results from Expanded Phase 2a Clinical Trial of Ovarest (oral leuprolide tablet) for Endometriosis

07.03 2018.

BOONTON, N.J., June 26, 2018 /PRNewswire/ – Enteris BioPharma, Inc., an oral dosage form biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, announced positive results today… Details

HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDA

07.01 2018.

SAN DIEGO–(BUSINESS WIRE)–Jun. 21, 2018– Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important… Details

FDA Grants Priority Review to Genentech’s Baloxavir Marboxil for the Treatment of Influenza

07.01 2018.

South San Francisco, CA — June 25, 2018 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted Priority Review… Details

Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache

06.19 2018.

JERUSALEM–(BUSINESS WIRE)–Jun. 15, 2018– Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced a change in the clinical development program of fremanezumab in chronic cluster headache. The ENFORCE Phase III clinical… Details

Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy

06.19 2018.

SOUTH SAN FRANCISCO, Calif., June 16, 2018 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq:CYTK) today announced data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) were presented in an oral… Details